Dishman Carbogen Amcis Ltd Q2FY26 – When Swiss Precision Meets Gujarati Jugaad and Still Manages a 89% Profit Jump!
1. At a Glance
Welcome to the world of Dishman Carbogen Amcis Ltd (DCAL) – a global CRAMS (Contract Research and Manufacturing Services) powerhouse where Swiss chemistry meets Indian frugality, and the result this quarter was a rather pleasing explosion: Q2FY26 PAT up 88.8% QoQ to ₹65.3 crore on revenue of ₹653 crore. This despite sales dropping 17% QoQ – because apparently, profit now runs on Swiss precision, not Indian sales growth.
The stock closed at ₹298, up nearly 60% in six months, giving a market cap of ₹4,666 crore. At a P/E of 31.2x, it’s not cheap – but hey, who counts P/E when the FDA smiles and Switzerland approves? With ROCE at 2.42% and ROE still negative (-0.32%), investors seem to be betting on the “future chemistry” rather than the past math. Debt stands at ₹2,559 crore, EV/EBITDA at 10.5x, and the stock trades at just 0.73x book value — meaning you can technically buy the assets cheaper than their written worth.
But before you jump to conclusions, remember: this is a company that has survived FDA inspections, EDQM audits, and even the demise of its founding chairman — all in one year. If resilience were a molecule, DCAL would have patented it.
2. Introduction – The Swiss Knife of Pharma Manufacturing
There are two kinds of Indian pharma companies: those who make tablets, and those who make the tablets for those who make tablets. Dishman Carbogen Amcis belongs firmly in the second category — a behind-the-scenes genius mixing Swiss discipline, British paperwork, and Gujarati ambition.
Once known for its Vitamin D3 molecules and disinfectants, DCAL today earns 88% of its revenue from CRAMS — a fancy term for “we make your drugs, you keep your brand.” The company’s global reach spans Switzerland, the UK, France, China, the Netherlands, and of course, Bavla (Gujarat) – where their famous high-potent (HIPO) facility stands, doing things that probably require more safety gear than a space mission.
FY25 and FY26 have been an eventful chemistry experiment for Dishman. On one hand, it completed multiple regulatory inspections — EDQM, PMDA Japan, and US FDA — all without a single red flag. On the other hand, it navigated through leadership transitions after the passing of Dr. Janmejay Vyas, the founder, in May 2025.
But investors have started noticing. With an annualized EPS of ₹34.8 and revenue climbing back towards pre-COVID peaks, DCAL seems to be finally converting its scientific muscle into shareholder serotonin.
Still, the journey is far from over — the company’s interest coverage ratio is just 1.77, so finance costs continue to sting. But hey, at least they’re getting inspected by FDA and not the bank auditors.
3. Business Model – WTF Do They Even Do?
If you’ve ever wondered how drugs go from lab scribbles to life-saving vials, Dishman is that uncredited lab technician who does everything except getting the Nobel Prize.
Their business model splits neatly into two molecules:
1. CRAMS Vertical (88% of revenue) – The jewel in their flask, this segment supports global innovators from R&D to full-scale manufacturing. Through subsidiaries like CARBOGEN AMCIS (Switzerland) and Dishman India, they provide process development, scale-up, clinical batches, and commercial production. Basically, Big Pharma dreams it, Dishman cooks it.
2. Marketable Molecules (12% of revenue) – This is the “cash cow plus nostalgia” division:
Specialty Chemicals: Wittig reagents, quaternary ammonium salts — products that only a chemist or an interrogator would love.
Vitamins & Analogues: Especially Vitamin D3 — they can make up to 1,000 MT annually.
Generic APIs & Disinfectants: The COVID-era saviours still hang around, making sure DCAL’s plants don’t just smell of solvents but also success.
Their customer base spans 250 clients, mostly small-to-mid-size European pharma companies, which means high-value, low-drama business. Exports contribute ~90% of revenue, giving them enough foreign currency to survive another rupee slide.
Oh, and they have 25 manufacturing plants and 28 R&D labs across continents. About 950 scientists, 50% of whom hold PhDs. In short — they make molecules smartly, and their employees could probably explain relativity before breakfast.
4. Financials Overview – The Chemistry of a Turnaround
Metric
Latest Qtr (Q2FY26)
YoY Qtr (Q2FY25)
Prev Qtr (Q1FY26)
YoY %
QoQ %
Revenue (₹ Cr)
653
789
708
-17.2%
-7.8%
EBITDA (₹ Cr)
149
147
141
+1.4%
+5.7%
PAT (₹ Cr)
65.3
33
23
+98%
+188%
EPS (₹)
4.16
2.11
1.49
+97%
+179%
Annualized EPS = ₹16.64, implying a P/E of ~17.9x on current price ₹298.
Commentary: When your revenue shrinks but profit doubles, you know your CFO is finally winning Excel battles. Q2FY26 was that kind of quarter —
